Lenvatinib improves survival in radioiodine-refractory thyroid cancer
by Bruce Sylvester: Lenvatinib treatment has resulted in significant improvement in progression-free survival among patients with advanced radioiodine-refractory thyroid cancer, researchers from a Phase III trial reported in… read more.